OAM
NKTR icon

Oppenheimer Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Oppenheimer Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-210
Closed -$335K – 1166
2018
Q1 		$335K Buy
+210
New +$271K 0.01% 901
2017
Q4 		– Sell
-359
Closed -$129K – 1339
2017
Q3 		$129K Buy
+359
New +$112K ﹤0.01% 1145

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Oppenheimer Asset Management's NKTR Position: Q2 2018 in Review

Oppenheimer Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 210 shares — an estimated $335K sold.

Oppenheimer Asset Management first reported a position in NKTR in Q3 2017 and held it in 2 quarters. The position peaked at $335K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Oppenheimer Asset Management reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Oppenheimer Asset Management sold 210 Nektar Therapeutics shares in Q2 2018, an estimated $335K.
  • Oppenheimer Asset Management first reported a position in Nektar Therapeutics in Q3 2017 and held it in 2 quarters.
  • Oppenheimer Asset Management's Nektar Therapeutics position peaked at $335K in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Oppenheimer Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.